BUSINESS

• Nipro Pharma Forms Capital Tie-Up with Vietnam’s Mekophar
  November 16, 2016

• Sawai Might See Teva-Takeda JV Impact on Distribution Channel: President
  November 15, 2016

• Ethical Drug Sales Down 5.6% in September: Crecon Report
  November 15, 2016

• Pace of Generic Substitution Slowing at Pharmacies: Sawai President
  November 15, 2016

• Regenerative Medicine Market to Expand to 142.1 Billion Yen in 2030: Fuji Keizai
  November 11, 2016

• Opdivo Significantly Prolongs OS in Gastric Cancer Patients in PIII Study: Ono
  November 11, 2016

• Takecab Most Promoted Drug in September: Anterio
  November 11, 2016

• Top 4 Wholesalers See Lower Sales in April-September If Hep C Meds Excluded
  November 11, 2016

• Enrollment Completed for PIII Adcetris Study for Mature T-Cell Lymphoma: Takeda
  November 10, 2016

• Nippon Shinyaku’s DMD Med Gets Fast Track Status in US
  November 10, 2016

• Kipres Generics Earn Bronchial Asthma Indication in Droves
  November 10, 2016

• MSD to Seek Keytruda Listing after Adding Lung Cancer Indication
  November 10, 2016

• Takeda to Collaborate with 2 Universities on Application of Miniature Liver Technology to Drug Discovery Research
  November 10, 2016

• Kipres AG’s Market Penetration Faster than Expected: Kyorin President
  November 9, 2016

• Teva Takeda Pharma “Not a Threat” at Present: Nichi-Iko Pres. Tamura
  November 9, 2016

• BIKEN, Mitsubishi Tanabe to Form Vaccine JV Next May
  November 8, 2016

• Current Drug Pricing System Became Unfit for New Drugs Like Opdivo: Ono Chief
  November 8, 2016

• Ono's Revenue and Profits Soar as Opdivo Sales Jump 1,714%
  November 8, 2016

• MSD’s New Dual Oral Hep C Therapy to Challenge Harvoni; Effective Regardless of Resistance Mutations, Renal Impairment
  November 8, 2016

• Japan Diabetes Market Likely to Grow 40% by 2024: Fuji Keizai
  November 7, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 461
• 462
• 463
• 464
• 465
• 466
• 467
• 468
• 469
• …
• Next ›
• 最終 »